Novo Nordisk’s diabetic tablet, Libers, has shown promising cardiovascular benefits in late-stage trials, according to results presented at the American Cardiology annual session in Chicago. The tablet demonstrated a 14% reduction in the risk of cardiovascular-related death, heart attacks, and strokes over an average of four years among patients with diabetes and heart disease, regardless of chronic kidney disease. This positions Libers as a potential new treatment option for patients who prefer oral medications over injections. The company has sought approvals for the expanded use of Libers in the U.S. and EU to mitigate serious cardiovascular risks. The results are beneficial not only for patients wary of injections but also align with ongoing developments by other pharmaceutical companies, such as Eli Lilly, which is exploring oral GLP-1 medications for various conditions. The study involved over 9,600 patients aged 50 and older.
Source link
